Parallax Volatility Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.01M Sell
50,000
-74,000
-60% -$1.59M 0.01% 784
2025
Q4
$3.11M Hold
124,000
0.01% 820
2025
Q3
$2.81M Hold
124,000
﹤0.01% 824
2025
Q2
$2.15M Hold
124,000
﹤0.01% 857
2025
Q1
$2.71M Sell
124,000
-74,500
-38% -$2.06M 0.01% 783
2024
Q4
$6.33M Buy
198,500
+49,500
+33% +$1.49M 0.01% 737
2024
Q3
$4.3M Buy
+149,000
New +$5.52M 0.01% 853
2024
Q1
Sell
-27,700
Closed -$1.66M 1805
2023
Q4
$1.66M Buy
27,700
+21,500
+347% +$1.09M ﹤0.01% 1227
2023
Q3
$236K Sell
6,200
-10,800
-64% -$474K ﹤0.01% 1776
2023
Q2
$1.55M Sell
17,000
-61,500
-78% -$5.31M ﹤0.01% 1234
2023
Q1
$5.18M Sell
78,500
-4,700
-6% -$271K 0.01% 843
2022
Q4
$4.3M Buy
+83,200
New +$4.41M 0.01% 1089
2022
Q3
Sell
-135,700
Closed -$6.14M 3041
2022
Q2
$6.14M Sell
135,700
-14,300
-10% -$652K 0.01% 904
2022
Q1
$7.62M Buy
+150,000
New +$6.62M ﹤0.01% 839
2020
Q3
Sell
-25,800
Closed -$843K 3027
2020
Q2
$843K Buy
+25,800
New +$829K ﹤0.01% 1800
2020
Q1
Sell
-1,400
Closed -$43K 2447
2019
Q4
$43K Buy
+1,400
New +$38.7K ﹤0.01% 2229

Other funds holding APLS

Parallax Volatility Advisers's APLS Position: Q3 2025 in Review

Parallax Volatility Advisers sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 24,443 shares — an estimated $570K sold.

Parallax Volatility Advisers first reported a position in APLS in Q4 2017 and held it in 12 quarters. The position peaked at $5.27M in Q3 2022. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Parallax Volatility Advisers reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 24,443 Apellis Pharmaceuticals shares in Q3 2025, an estimated $570K.
  • Parallax Volatility Advisers first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 12 quarters.
  • Parallax Volatility Advisers's Apellis Pharmaceuticals position peaked at $5.27M in Q3 2022.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.